Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Queensland Health
Medtronic
Argus Health
Healthtrust
Julphar
Baxter
Fuji
US Department of Justice
Citi

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,071,613

« Back to Dashboard

Which drugs does patent 8,071,613 protect, and when does it expire?

Patent 8,071,613 protects AMITIZA and is included in one NDA.

This patent has thirty-seven patent family members in twenty-four countries.
Summary for Patent: 8,071,613
Title:Anti-constipation composition
Abstract: An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): ##STR00001## where X.sub.1 and X.sub.2 are preferably both fluorine atoms. The composition can be used to treat constipation without substantive side-effects, such as stomachache.
Inventor(s): Ueno; Ryuji (Potomac, MD)
Assignee: Sucampo AG (Zurich, CH)
Application Number:11/142,251
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,071,613

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-002 Apr 29, 2008 RX Yes No ➤ Subscribe ➤ Subscribe METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENTWITH IRRITABLE BOWEL SYNDROME ➤ Subscribe
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-001 Jan 31, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT ➤ Subscribe
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-001 Jan 31, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,071,613

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,414,016 Anti-constipation composition ➤ Subscribe
6,610,732 Anti-constipation composition ➤ Subscribe
8,748,454 Anti-constipation composition ➤ Subscribe
8,114,890 Anti-constipation composition ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,071,613

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 030609 ➤ Subscribe
Argentina 100291 ➤ Subscribe
Austria 476975 ➤ Subscribe
Australia 2001282615 ➤ Subscribe
Australia 8261501 ➤ Subscribe
Brazil 0114042 ➤ Subscribe
Brazil PI0114042 ➤ Subscribe
Canada 2419741 ➤ Subscribe
China 100335049 ➤ Subscribe
China 1655776 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Novartis
Accenture
Daiichi Sankyo
Merck
Moodys
Deloitte
Farmers Insurance
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot